Covalon Technologies Ltd. (CVALF)
USD 2.42
(-1.63%)
USD 2.42
(-1.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.1 Million CAD | -0.68% |
| 2022 | 6.14 Million CAD | -14.68% |
| 2021 | 7.2 Million CAD | -71.83% |
| 2020 | 25.59 Million CAD | 3.7% |
| 2019 | 24.67 Million CAD | 274.85% |
| 2018 | 6.58 Million CAD | 120.47% |
| 2017 | 2.98 Million CAD | 11.38% |
| 2016 | 2.68 Million CAD | -5.76% |
| 2015 | 2.84 Million CAD | 16.88% |
| 2014 | 2.43 Million CAD | -10.65% |
| 2013 | 2.72 Million CAD | -0.19% |
| 2012 | 2.72 Million CAD | 18.31% |
| 2011 | 2.3 Million CAD | -16.1% |
| 2010 | 2.74 Million CAD | 42.76% |
| 2009 | 1.92 Million CAD | -15.43% |
| 2008 | 2.27 Million CAD | -14.1% |
| 2007 | 2.65 Million CAD | 402.67% |
| 2006 | 527.43 Thousand CAD | -25.49% |
| 2005 | 707.83 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.61 Million CAD | -24.42% |
| 2024 Q3 | 4.85 Million CAD | 38.64% |
| 2024 Q2 | 3.49 Million CAD | -24.18% |
| 2023 FY | 6.1 Million CAD | -0.68% |
| 2023 Q1 | 6.54 Million CAD | 6.4% |
| 2023 Q2 | 5.75 Million CAD | -11.98% |
| 2023 Q4 | 6.1 Million CAD | 14.56% |
| 2023 Q3 | 5.33 Million CAD | -7.42% |
| 2022 FY | 6.14 Million CAD | -14.68% |
| 2022 Q3 | 4.61 Million CAD | -13.87% |
| 2022 Q1 | 6.1 Million CAD | -15.36% |
| 2022 Q4 | 6.14 Million CAD | 33.22% |
| 2022 Q2 | 5.35 Million CAD | -12.15% |
| 2021 Q4 | 7.2 Million CAD | -70.42% |
| 2021 Q1 | 24.14 Million CAD | -5.65% |
| 2021 Q3 | 24.36 Million CAD | -2.14% |
| 2021 FY | 7.2 Million CAD | -71.83% |
| 2021 Q2 | 24.9 Million CAD | 3.13% |
| 2020 Q4 | 25.59 Million CAD | -4.75% |
| 2020 Q2 | 26.9 Million CAD | 5.34% |
| 2020 Q3 | 26.86 Million CAD | -0.13% |
| 2020 FY | 25.59 Million CAD | 3.7% |
| 2020 Q1 | 25.53 Million CAD | 3.49% |
| 2019 Q2 | 25.09 Million CAD | 2.65% |
| 2019 Q4 | 24.67 Million CAD | 3.06% |
| 2019 FY | 24.67 Million CAD | 274.85% |
| 2019 Q1 | 24.44 Million CAD | 271.38% |
| 2019 Q3 | 23.94 Million CAD | -4.6% |
| 2018 Q1 | 3.01 Million CAD | 0.93% |
| 2018 Q4 | 6.58 Million CAD | 120.93% |
| 2018 FY | 6.58 Million CAD | 120.47% |
| 2018 Q2 | 2.9 Million CAD | -3.64% |
| 2018 Q3 | 2.97 Million CAD | 2.6% |
| 2017 Q3 | 2.77 Million CAD | -10.95% |
| 2017 Q2 | 3.11 Million CAD | 25.04% |
| 2017 Q4 | 2.98 Million CAD | 7.66% |
| 2017 FY | 2.98 Million CAD | 11.38% |
| 2017 Q1 | 2.49 Million CAD | -7.09% |
| 2016 Q3 | 2.69 Million CAD | -29.1% |
| 2016 Q1 | 3.56 Million CAD | 25.2% |
| 2016 FY | 2.68 Million CAD | -5.76% |
| 2016 Q4 | 2.68 Million CAD | -0.54% |
| 2016 Q2 | 3.8 Million CAD | 6.73% |
| 2015 Q4 | 2.84 Million CAD | 3.2% |
| 2015 FY | 2.84 Million CAD | 16.88% |
| 2015 Q3 | 2.75 Million CAD | -4.79% |
| 2015 Q2 | 2.89 Million CAD | 7.99% |
| 2015 Q1 | 2.68 Million CAD | 10.16% |
| 2014 FY | 2.43 Million CAD | -10.65% |
| 2014 Q1 | 3.09 Million CAD | 13.74% |
| 2014 Q3 | 2.82 Million CAD | -2.78% |
| 2014 Q2 | 2.9 Million CAD | -6.11% |
| 2014 Q4 | 2.43 Million CAD | -13.94% |
| 2013 Q4 | 2.72 Million CAD | -5.09% |
| 2013 Q2 | 2.66 Million CAD | 12.27% |
| 2013 Q1 | 2.36 Million CAD | -13.19% |
| 2013 FY | 2.72 Million CAD | -0.19% |
| 2013 Q3 | 2.86 Million CAD | 7.89% |
| 2012 Q2 | 2.35 Million CAD | 3.01% |
| 2012 Q1 | 2.28 Million CAD | -0.97% |
| 2012 Q3 | 2.29 Million CAD | -2.28% |
| 2012 Q4 | 2.72 Million CAD | 18.68% |
| 2012 FY | 2.72 Million CAD | 18.31% |
| 2011 Q1 | 2.27 Million CAD | -17.4% |
| 2011 FY | 2.3 Million CAD | -16.1% |
| 2011 Q3 | 1.64 Million CAD | 4.34% |
| 2011 Q4 | 2.3 Million CAD | 40.34% |
| 2011 Q2 | 1.57 Million CAD | -30.64% |
| 2010 Q3 | 3.29 Million CAD | 106.38% |
| 2010 Q4 | 2.74 Million CAD | -16.56% |
| 2010 Q1 | 1.65 Million CAD | -13.84% |
| 2010 Q2 | 1.59 Million CAD | -3.78% |
| 2010 FY | 2.74 Million CAD | 42.76% |
| 2009 Q3 | 2.14 Million CAD | -14.43% |
| 2009 Q2 | 2.5 Million CAD | -0.07% |
| 2009 Q4 | 1.92 Million CAD | -10.15% |
| 2009 FY | 1.92 Million CAD | -15.43% |
| 2009 Q1 | 2.5 Million CAD | 10.06% |
| 2008 Q2 | 2.2 Million CAD | -6.77% |
| 2008 Q1 | 2.36 Million CAD | -10.88% |
| 2008 Q4 | 2.27 Million CAD | 13.15% |
| 2008 FY | 2.27 Million CAD | -14.1% |
| 2008 Q3 | 2.01 Million CAD | -8.62% |
| 2007 FY | 2.65 Million CAD | 402.67% |
| 2007 Q2 | 2.81 Million CAD | 377.2% |
| 2007 Q3 | 2.67 Million CAD | -4.74% |
| 2007 Q4 | 2.65 Million CAD | -1.05% |
| 2007 Q1 | 589.38 Thousand CAD | 11.75% |
| 2006 Q4 | 527.43 Thousand CAD | 0.7% |
| 2006 FY | 527.43 Thousand CAD | -25.49% |
| 2006 Q1 | 884.23 Thousand CAD | 24.92% |
| 2006 Q2 | 666.21 Thousand CAD | -24.66% |
| 2006 Q3 | 523.76 Thousand CAD | -21.38% |
| 2005 Q3 | 714.02 Thousand CAD | -12.77% |
| 2005 FY | 707.83 Thousand CAD | 0.0% |
| 2005 Q1 | 1.01 Million CAD | 0.0% |
| 2005 Q4 | 707.83 Thousand CAD | -0.87% |
| 2005 Q2 | 818.59 Thousand CAD | -19.7% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 88.542% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 36.258% |
| SQZ Biotechnologies Company | 50.03 Million USD | 87.794% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 91.572% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 89.65% |
| Mesoblast Limited | 188.44 Million USD | 96.759% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -58.585% |
| Genus plc | 485 Million USD | 98.741% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -4.538% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -142.726% |
| Marizyme, Inc. | 26.67 Million USD | 77.104% |
| ContraFect Corporation | 32.53 Million USD | 81.225% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -60.731% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -208.27% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -59.57% |
| Intellipharmaceutics International Inc. | 12 Million USD | 49.139% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 48.143% |
| MultiCell Technologies, Inc. | 1617.67 USD | -377466.253% |
| Accustem Sciences Inc. | 1.07 Million USD | -465.934% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.111% |
| EV Biologics, Inc. | 2.11 Million USD | -188.774% |
| Q BioMed Inc. | 8.13 Million USD | 24.901% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 92.635% |
| Neon Bloom, Inc. | 1.22 Million USD | -398.101% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -18.689% |
| Biomind Labs Inc. | 1.49 Million USD | -307.562% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 97.498% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 66.812% |
| Skye Bioscience, Inc. | 14.07 Million USD | 56.597% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -203.85% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4198.375% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 35.476% |
| IMV Inc. | 37.93 Million USD | 83.898% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2936.942% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -6.299% |
| GB Sciences, Inc. | 5.41 Million USD | -12.74% |
| Alpha Cognition Inc. | 7.16 Million USD | 14.753% |
| HST Global, Inc. | 593.59 Thousand USD | -928.95% |
| CSL Limited | 18.62 Billion USD | 99.967% |
| Halberd Corporation | 728.71 Thousand USD | -738.152% |
| Enzolytics Inc. | 365.26 Million USD | 98.328% |
| Resverlogix Corp. | 67.39 Million USD | 90.937% |
| Affymax, Inc. | 8.87 Million USD | 31.149% |
| SYBLEU INC | 681.41 Thousand USD | -796.34% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -628.215% |
| argenx SE | 444.95 Million USD | 98.627% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 91.848% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -256.346% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 48.688% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -66.644% |
| AVAX Technologies, Inc. | 3.99 Million USD | -52.934% |
| Zenith Capital Corp. | 27.56 Thousand USD | -22054.507% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.539% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2459.26% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -63.559% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -797.102% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.855% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 32.452% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -9025.754% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -325.967% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 87.849% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -125.243% |
| BioStem Technologies, Inc. | 15.9 Million USD | 61.598% |
| ONE Bio Corp. | 27.49 Million USD | 77.787% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1214.351% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -22164.339% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -385.055% |
| Agentix Corp. | 2.51 Million USD | -143.284% |
| LadRx Corporation | 2.2 Million USD | -177.56% |
| Cell Source, Inc. | 15.8 Million USD | 61.36% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -13565.151% |
| Regen BioPharma, Inc. | 5.45 Million USD | -11.913% |
| Regen BioPharma, Inc. | 5.45 Million USD | -11.913% |
| NovAccess Global Inc. | 7.86 Million USD | 22.3% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 75.318% |
| Itoco Inc. | 1.65 Million USD | -269.463% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -197.713% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -0.972% |
| Kadimastem Ltd | 3.5 Million USD | -74.266% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1348.823% |
| CytoDyn Inc. | 127.89 Million USD | 95.224% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -14512.254% |
| Mobile Lads Corp. | 1.31 Million USD | -365.001% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -289.93% |
| Qrons Inc. | 1.48 Million USD | -310.272% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 44.702% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -655.171% |
| Rebus Holdings, Inc. | 5.24 Million USD | -16.516% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -0.096% |
| International Stem Cell Corporation | 5.27 Million USD | -15.743% |
| Bioxytran, Inc. | 3.24 Million USD | -87.96% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -875.981% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -32.285% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.102% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 72.568% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -201.561% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -11.496% |
| Neutra Corp. | 973.52 Thousand USD | -527.385% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 78.95% |
| PureTech Health plc | 125.58 Million USD | 95.136% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -62.565% |
| IXICO plc | 1.9 Million USD | -221.412% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 70.248% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.089% |
| CSL Limited | 18.62 Billion USD | 99.967% |
| Cellectis S.A. | 249.36 Million USD | 97.551% |